Invention:
Researchers at the University of Arizona have identified a novel, previously unrecognized harmful role of coagulation factor, Factor XII (FXII) and/or activated coagulation factor XIIa (fXII(a)) in modulating the progression of dilated cardiomyopathy and heart failure development. They have proposed fXII(a) as a new biotarget to treat dilated cardiomyopathy or heart failure.
Background:
Approximately 6.2 million Americans and 64.3 million people worldwide currently have heart failure, and those numbers are expected to grow 50% by 2035. Techniques (new or repurposed) that suppress fXII(a) levels/activity may be used to treat patients with cardiomyopathy and heart failure.
Applications:
- Treatment for heart failure
- Treatment for dilated cardiomyopathy
Advantages:
- Novel therapeutic
- Useful biotarget for treatment
